SPRING BK PHARMACEUTICALS IN's ticker is SBPH and the CUSIP is 849431101. A total of 52 filers reported holding SPRING BK PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,261,000 | -8.9% | 941,171 | 0.0% | 0.07% | -18.8% |
| Q2 2020 | $1,384,000 | +56.4% | 941,171 | -1.1% | 0.08% | +3.7% |
| Q1 2020 | $885,000 | -41.2% | 951,701 | 0.0% | 0.08% | -28.1% |
| Q4 2019 | $1,504,000 | -68.8% | 951,701 | -31.0% | 0.11% | -77.5% |
| Q3 2019 | $4,826,000 | +0.5% | 1,378,841 | +5.9% | 0.51% | -3.4% |
| Q2 2019 | $4,803,000 | -51.9% | 1,301,701 | +36.8% | 0.52% | -53.0% |
| Q1 2019 | $9,983,000 | +1.0% | 951,701 | 0.0% | 1.12% | -13.5% |
| Q4 2018 | $9,888,000 | -13.9% | 951,701 | -0.2% | 1.29% | +28.0% |
| Q3 2018 | $11,487,000 | +23.3% | 953,301 | +21.3% | 1.01% | +11.0% |
| Q2 2018 | $9,314,000 | -27.2% | 785,950 | -5.6% | 0.91% | -30.0% |
| Q1 2018 | $12,800,000 | +15.6% | 832,247 | +1.1% | 1.30% | -2.8% |
| Q4 2017 | $11,076,000 | +0.8% | 823,474 | +26.2% | 1.34% | -4.4% |
| Q3 2017 | $10,991,000 | +31.9% | 652,676 | +6.1% | 1.40% | +8.0% |
| Q2 2017 | $8,332,000 | – | 615,384 | – | 1.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 785,950 | $9,314,000 | 0.91% |
| Morse Asset Management, Inc | 177,500 | $2,103,000 | 0.58% |
| PARSONS CAPITAL MANAGEMENT INC/RI | 281,213 | $3,332,000 | 0.38% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 73,000 | $860,000 | 0.33% |
| TIEDEMANN ADVISORS, LLC | 412,049 | $4,883,000 | 0.31% |
| Private Capital Advisors, Inc. | 52,335 | $620,000 | 0.19% |
| SECTORAL ASSET MANAGEMENT INC | 131,656 | $1,560,000 | 0.17% |
| Lee Financial Co | 18,750 | $222,000 | 0.05% |
| Baker Brothers Advisors | 373,144 | $4,422,000 | 0.03% |
| Alyeska Investment Group, L.P. | 200,000 | $2,370,000 | 0.02% |